BTIG Research Reaffirms “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $40.00 target price on the biopharmaceutical company’s stock. BTIG Research’s price objective indicates a potential upside of 99.10% from the stock’s current price.

A number of other analysts have also recently commented on TBPH. Wall Street Zen cut shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Oppenheimer assumed coverage on shares of Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 target price on the stock. HC Wainwright raised their target price on shares of Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $27.80.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $20.09 on Tuesday. The stock has a 50 day moving average price of $19.07 and a 200 day moving average price of $15.84. The stock has a market capitalization of $1.02 billion, a PE ratio of 35.25 and a beta of 0.15. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The company had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. As a group, research analysts forecast that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the sale, the senior vice president owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. The trade was a 10.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds have recently bought and sold shares of the stock. Quarry LP acquired a new position in shares of Theravance Biopharma in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its stake in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC increased its position in Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.